Validation of the Hebrew Version of the Montreal Affective Voices.
1 other identifier
observational
120
1 country
1
Brief Summary
Today, no non-verbal auditory stimuli that assess mental processing are available in Israel. The goal of this study is to make available a validated set of auditory stimuli in Israel. We created a computerized Hebrew version of the Montreal Affective Voices (MAV). The MAV is a novel tool for assessing mental processing. The MAV consists of 90 nonverbal affect bursts corresponding to nine different emotions (such as anger, fear, happiness etc.) recorded by ten different actors. The uniqueness of these affective bursts is that they do not contain verbal context, but rather express affective moods using the vowel /a/ (as in "apple"). In this study, the investigators will verify the new Hebrew version of MAV in healthy control groups. Next, the investigators will compare the mental processing ability in young vs. old population, using the MAV test. In addition, the investigators will assess mental processing in two pathologic study groups (Parkinson's disease, major depressive disorder) using the MAV test. The investigators intend to use the MAV tool in future research in Parkinson's disease and depression.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 15, 2012
CompletedFirst Posted
Study publicly available on registry
January 19, 2012
CompletedStudy Start
First participant enrolled
February 1, 2012
CompletedJanuary 24, 2012
January 1, 2012
January 15, 2012
January 22, 2012
Conditions
Outcome Measures
Primary Outcomes (1)
Verifying the results achieved by Belin et al (2008) when using the Hebrew version of the MAV bursts in healthy control groups.
12 months
Study Arms (3)
healthy control group
Young (20-49) and Older (50-70) healthy group (n=60)
Parkinson's disease patients
(n=30).
Major depressive disorder patients
(n=30).
Eligibility Criteria
healthy group, Parkinson's disease patients, Major depressive disorder patients.
You may qualify if:
- Healthy group
- Parkinson's disease
- Major depressive disorder
- All participants will be competent and willing to give written informed consent. Patients over 65 and/or suspected to have a cognitive decline will be tested by the Mini-mental test and will be included in the study only if the score is above 26.
You may not qualify if:
- Non-competent or unable to give written informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hadassah Medical Organization,
Jerusalem, Israel
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 15, 2012
First Posted
January 19, 2012
Study Start
February 1, 2012
Last Updated
January 24, 2012
Record last verified: 2012-01